Revelation Biosciences, a US-based clinical-stage life sciences company focused on the development of immunologic-based therapies, said it has enrolled the first patient in the Phase 1b trial of its new proprietary intranasal drop formulation REVTx-99 targeting allergic rhinitis and chronic nasal congestion without polyps. The randomised, double-bind, placebo controlled study in Australia is expected to enrol 28 participants. 

According to the company,  the secondary endpoints in the study includes allergy symptoms (Total Nasal Symptom Score) and peak nasal inspiratory flow elicited by nasal allergen challenge, the results of which are expected to be out in the first half of 2022. REVTx-99 is indicated at respiratory viral infections and is broadly applicable to most infectious viruses including influenza A, influenza B, parainfluenza, rhinovirus, respiratory syncytial virus (RSV), SARS-CoV-2, and its variants. The active ingredient in the formulation stimulates the nasal (mucosal) innate immune system via interaction with toll-like receptor 4 (TLR4) to produce protective cytokines including interferons and interferon-related proteins. These protective cytokines work in concert to blunt the ability of an invading virus to proliferate and survive. Phase 1 data had shown REVTx-99 to be well-tolerated and to significantly increase intranasal protective cytokines.